|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/22/24 Skye Bioscience, Inc. 10-K 12/31/23 98:12M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.04M
2: EX-2.9 Agreement and Plan of Merger and Reorganization HTML 692K
3: EX-3.1 Articles of Incorporation of Registrant, as HTML 68K
Amended
4: EX-4.14 Instrument Defining the Rights of Security Holders HTML 37K
5: EX-21.1 Subsidiaries of the Registrant HTML 29K
6: EX-23.1 Consent of Marcum LLP HTML 27K
11: EX-97.1 Compensation Recoupment Policy HTML 39K
7: EX-31.1 Certification of Principal Executive Officer HTML 31K
8: EX-31.2 Certification of Principal Financial and HTML 31K
Accounting Officer
9: EX-32.1 Certification of Principal Executive Officer HTML 29K
10: EX-32.2 Certification of Principal Financial and HTML 29K
Accounting Officer
17: R1 Cover HTML 87K
18: R2 Audit Information HTML 32K
19: R3 Consolidated Balance Sheets HTML 136K
20: R4 Consolidated Balance Sheets (Parentheticals) HTML 48K
21: R5 Consolidated Statements of Operations HTML 102K
22: R6 Consolidated Statements of Cash Flows HTML 171K
23: R7 Consolidated Statements of Cash Flows HTML 32K
(Parentheticals)
24: R8 Consolidated Statements of Stockholders' Equity HTML 96K
25: R9 Consolidated Statements of Stockholders' Equity HTML 31K
(Parentheticals)
26: R10 Nature of Operations and Business Activities HTML 37K
27: R11 Summary of Significant Accounting Policies HTML 84K
28: R12 Asset Acquisitions HTML 87K
29: R13 Prepaid Expenses, Other Current Assets and Other HTML 56K
Current Liabilities
30: R14 Warrants and Derivative Liabilities HTML 93K
31: R15 Debt HTML 63K
32: R16 Stockholders' Equity and Capitalization HTML 50K
33: R17 Stock-Based Compensation HTML 92K
34: R18 Loss Per Share of Common Stock HTML 50K
35: R19 Income Taxes HTML 101K
36: R20 Licensed Intellectual Property HTML 35K
37: R21 Related Party Matters HTML 41K
38: R22 Commitments and Contingencies HTML 52K
39: R23 Subsequent Events HTML 34K
40: R24 Summary of Significant Accounting Policies HTML 132K
(Policies)
41: R25 Asset Acquisitions (Tables) HTML 104K
42: R26 Prepaid Expenses, Other Current Assets and Other HTML 60K
Current Liabilities (Tables)
43: R27 Warrants and Derivative Liabilities (Tables) HTML 94K
44: R28 Debt (Tables) HTML 51K
45: R29 Stockholders' Equity and Capitalization (Tables) HTML 42K
46: R30 Stock-Based Compensation (Tables) HTML 90K
47: R31 Loss Per Share of Common Stock (Tables) HTML 52K
48: R32 Income Taxes (Tables) HTML 99K
49: R33 Commitments and Contingencies (Tables) HTML 44K
50: R34 Nature of Operations and Business Activities HTML 69K
(Details)
51: R35 Summary of Significant Accounting Policies HTML 62K
(Details)
52: R36 Asset Acquisitions - BRB Acquisition - Narrative HTML 41K
(Details)
53: R37 Asset Acquisitions - Schedule of BRB Acquisition HTML 47K
(Details)
54: R38 Asset Acquisitions - Acquisition of Emerald Health HTML 37K
Therapeutics, Inc., Narrative (Details)
55: R39 Asset Acquisitions - Schedule of EHT Asset HTML 65K
Acquisition (Details)
56: R40 Asset Acquisitions - Footnote Information From HTML 99K
Schedule of Asset Acquisition (Details)
57: R41 Asset Acquisitions - Assumptions to Value Options HTML 50K
(Details)
58: R42 Asset Acquisitions - Assumptions to Value Warrants HTML 46K
(Details)
59: R43 Asset Acquisitions - Divestiture of Emerald Health HTML 39K
Therapeutics Canada, Inc. - Narrative (Details)
60: R44 Asset Acquisitions - Divestiture of VDL - HTML 57K
Narrative (Details)
61: R45 Prepaid Expenses, Other Current Assets and Other HTML 34K
Current Liabilities - Schedule of Prepaid Expenses
(Details)
62: R46 Prepaid Expenses, Other Current Assets and Other HTML 39K
Current Liabilities - Schedule Of Other Current
Assets (Details)
63: R47 Prepaid Expenses, Other Current Assets and Other HTML 47K
Current Liabilities - Schedule of Other Current
Liabilities (Details)
64: R48 Warrants and Derivative Liabilities - Schedule of HTML 74K
Warrants Vested and Outstanding (Details)
65: R49 Warrants and Derivative Liabilities - Narrative HTML 95K
(Details)
66: R50 Warrants and Derivative Liabilities - Schedule of HTML 80K
Input and Valuation Techniques Used to Value
Warrant Liabilities (Details)
67: R51 Warrants and Derivative Liabilities - Derivative HTML 42K
Liabilities (Details)
68: R52 Debt - Schedule of Debt (Details) HTML 44K
69: R53 Debt - Narrative (Details) HTML 116K
70: R54 Debt - Interest Expense (Details) HTML 47K
71: R55 Stockholders? Equity and Capitalization - Reserved HTML 53K
Shares of Common Stock (Details)
72: R56 Stockholders? Equity and Capitalization - HTML 121K
Narrative (Details)
73: R57 Stock-Based Compensation - Narrative (Details) HTML 128K
74: R58 Stock-Based Compensation - Shares Available for HTML 44K
Future Grant (Details)
75: R59 Stock-Based Compensation - Summary of Option HTML 80K
(Details)
76: R60 Stock-Based Compensation - Fair Value Assumptions HTML 58K
of Stock Option Granted (Details)
77: R61 Stock-Based Compensation - Restricted Stock Awards HTML 55K
(Details)
78: R62 Stock-Based Compensation - Stock-based HTML 42K
Compensation Expense (Details)
79: R63 Loss Per Share of Common Stock - Basic and Diluted HTML 54K
Net Loss Per Share (Details)
80: R64 Loss Per Share of Common Stock - Anti-dilutive HTML 43K
Securities (Details)
81: R65 Income Taxes - Components of Income (Loss) Before HTML 37K
the Income Tax Provision (Benefit) (Details)
82: R66 Income Taxes - Components of Income Tax Expense HTML 38K
(Details)
83: R67 Income Taxes - Narrative (Details) HTML 60K
84: R68 Income Taxes - Deferred Income Tax Assets HTML 62K
(Details)
85: R69 Income Taxes - Provision for Income Taxes on HTML 62K
Earnings (Details)
86: R70 Income Taxes - Unrecognized Tax Positions HTML 37K
(Details)
87: R71 Licensed Intellectual Property (Details) HTML 52K
88: R72 Related Party Matters (Details) HTML 98K
89: R73 Commitments and Contingencies - Narrative HTML 72K
(Details)
90: R74 Commitments and Contingencies - Weighted Average HTML 32K
Remaining Lease Term and Discount Rate (Details)
91: R75 Commitments and Contingencies - Schedule of Future HTML 40K
Minimum Lease Payments (Details)
92: R76 Commitments and Contingencies - Current and HTML 33K
Noncurrent Portions of Operating Lease (Details)
93: R77 Subsequent Events (Details) HTML 98K
95: XML IDEA XML File -- Filing Summary XML 172K
98: XML XBRL Instance -- skye-20231231_htm XML 1.94M
94: EXCEL IDEA Workbook of Financial Report Info XLSX 214K
13: EX-101.CAL XBRL Calculations -- skye-20231231_cal XML 252K
14: EX-101.DEF XBRL Definitions -- skye-20231231_def XML 1.16M
15: EX-101.LAB XBRL Labels -- skye-20231231_lab XML 2.11M
16: EX-101.PRE XBRL Presentations -- skye-20231231_pre XML 1.51M
12: EX-101.SCH XBRL Schema -- skye-20231231 XSD 268K
96: JSON XBRL Instance as JSON Data -- MetaLinks 561± 862K
97: ZIP XBRL Zipped Folder -- 0001516551-24-000048-xbrl Zip 1.49M
| Document |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/22/24 | |||
| Filed on: | 3/21/24 | |||
| For Period end: | 12/31/23 | |||
| 12/31/22 | 10-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/10/24 Skye Bioscience, Inc. S-3 6:1.3M Workiva Inc Wde… FA01/FA 5/10/24 Skye Bioscience, Inc. S-3 4:333K Workiva Inc Wde… FA01/FA 5/10/24 Skye Bioscience, Inc. 10-Q 3/31/24 59:4.2M 4/24/24 Skye Bioscience, Inc. POS AM 4:404K Workiva Inc Wde… FA01/FA 4/04/24 Skye Bioscience, Inc. S-1/A 87:9.1M Workiva Inc Wde… FA01/FA 3/27/24 Skye Bioscience, Inc. S-1 90:12M Workiva Inc Wde… FA01/FA |